Literature DB >> 34861372

Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

T Powles1, J Bellmunt2, E Comperat3, M De Santis4, R Huddart5, Y Loriot6, A Necchi7, B P Valderrama8, A Ravaud9, S F Shariat10, B Szabados11, M S van der Heijden12, S Gillessen13.   

Abstract

Entities:  

Keywords:  antibody drug conjugates; bladder cancer; fibroblast growth factor receptor inhibitors; immune checkpoint inhibitors; platinum-based chemotherapy; urothelial carcinoma

Mesh：

Substances：

Year:  2021        PMID： 34861372     DOI： 10.1016/j.annonc.2021.11.012

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  18 in total

1.  An integrative approach for identification of smoking-related genes involving bladder cancer.

Authors:  Fang Gao; Huiqin Li; Zhenguang Mao; Yanping Xiao; Mulong Du; Shizhi Wang; Rui Zheng; Zhengdong Zhang; Meilin Wang
Journal:  Arch Toxicol       Date:  2022-10-12       Impact factor: 6.168

2.  Efficacy of Vinflunine for Patients with Metastatic Urothelial Cancer after Immune Checkpoint Inhibitor Pretreatment-A Retrospective Multicenter Analysis.

Authors:  Felix Riedel; Mara Münker; Florian Roghmann; Johannes Breyer; Marco J Schnabel; Maximilian Burger; Danijel Sikic; Thomas Büttner; Manuel Ritter; Kiriaki Hiller; Felix Wezel; Christian Bolenz; Friedemann Zengerling
Journal:  Cancers (Basel)       Date:  2022-06-09       Impact factor: 6.575

3.  Complete and long-lasting response to immunotherapy: A case report of urothelial cancer.

Authors:  Diogo J Silva; Alexandra Mesquita
Journal:  Medicine (Baltimore)       Date:  2022-06-17       Impact factor: 1.817

Review 4.  Advances in Diagnosis and Therapy for Bladder Cancer.

Authors:  Xinzi Hu; Guangzhi Li; Song Wu
Journal:  Cancers (Basel)       Date:  2022-06-29       Impact factor: 6.575

Review 5.  Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy?

Authors:  Mário Fontes-Sousa; Helena Magalhães; Alicia Oliveira; Filipa Carneiro; Filipa Palma Dos Reis; Pedro Silvestre Madeira; Sara Meireles
Journal:  Adv Ther       Date:  2022-01-13       Impact factor: 3.845

Review 6.  New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond.

Authors:  Alessandro Audisio; Consuelo Buttigliero; Marco Donatello Delcuratolo; Elena Parlagreco; Marco Audisio; Antonio Ungaro; Rosario Francesco Di Stefano; Lavinia Di Prima; Fabio Turco; Marcello Tucci
Journal:  Cells       Date:  2022-01-21       Impact factor: 6.600

7.  Effect of neoadjuvant chemotherapy on overall survival of patients with T2-4aN0M0 bladder cancer: A systematic review and meta-analysis according to EAU COVID-19 recommendation.

Authors:  Dong Hyuk Kang; Kang Su Cho; Young Joon Moon; Doo Yong Chung; Hae Do Jung; Joo Yong Lee
Journal:  PLoS One       Date:  2022-04-21       Impact factor: 3.240

Review 8.  The Role of The Tumor Microbiome in Tumor Development and Its Treatment.

Authors:  Yan Chen; Fa-Hong Wu; Peng-Qiang Wu; Hong-Yun Xing; Tao Ma
Journal:  Front Immunol       Date:  2022-07-15       Impact factor: 8.786

9.  Antibladder Cancer Effects of Excavatolide C by Inducing Oxidative Stress, Apoptosis, and DNA Damage In Vitro.

Authors:  Che-Wei Yang; Tsu-Ming Chien; Chia-Hung Yen; Wen-Jeng Wu; Jyh-Horng Sheu; Hsueh-Wei Chang
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-24

10.  Bladder Tissue Microbiome Composition in Patients of Bladder Cancer or Benign Prostatic Hyperplasia and Related Human Beta Defensin Levels.

Authors:  Bassel Mansour; Ádám Monyók; Márió Gajdács; Balázs Stercz; Nóra Makra; Kinga Pénzes; István Vadnay; Dóra Szabó; Eszter Ostorházi
Journal:  Biomedicines       Date:  2022-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.